ArticleMalaria journal2018
Isolation and characterization of malaria PfHRP2 specific V
Article in Malaria journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- In vitro selection of VNAR antibodies using bioinformatics-based library design and cDNA display.Biotechnology reports (Amsterdam, Netherlands) · 2026Article
- An Optimized and Systematically Integrated Expression, Extraction, and Purification Strategy Enabling Efficient Production of TCR-Like Antibodies in Escherichia coli.Current microbiology · 2026Article
- Construction of an Enhanced Phage Display Library of Artificially Randomized vNARs from Cloudy Catshark (Scyliorhinus Torazame) and Screening against Miamiensis Avidus.Marine biotechnology (New York, N.Y.) · 2026Article
- Reinventing malaria control: hierarchical intervention strategies for African settings based on the microbiota-barrier-innate immunity axis.Frontiers in immunology · 2026Review
- Construction and application of a large capacity VNAR library from the whitespotted bamboo shark (Acta pharmaceutica Sinica. B · 2025Article
- VNAR: shark single-domain antibodies for the new era of medical biotechnology.Frontiers in immunology · 2025Review
- Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?Marine drugs · 2023Review
- Review
- Chimeric Peptides fromToxins · 2023Article
- First pan-specific vNAR against human TGF-β as a potential therapeutic application: in silico modeling assessment.Scientific reports · 2023Article
- VNAR development through antigen immunization of Japanese topeshark (Frontiers in bioengineering and biotechnology · 2023Article
- Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.Biomedical engineering advances · 2022Review
- Identification of Anti-TNFα VNAR Single Domain Antibodies from Whitespotted Bambooshark (Marine drugs · 2022Article
- Overview, Generation, and Significance of Variable New Antigen Receptors (VNARs) as a Platform for Drug and Diagnostic Development.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Shark New Antigen Receptor (IgNAR): Structure, Characteristics and Potential Biomedical Applications.Cells · 2021Review
- Bamboo Shark as a Small Animal Model for Single Domain Antibody Production.Frontiers in bioengineering and biotechnology · 2021Article
- Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.Frontiers in cellular and infection microbiology · 2021Review
- Diagnostic and therapeutic potential of shark variable new antigen receptor (VNAR) single domain antibody.International journal of biological macromolecules · 2020Review
- Ancient species offers contemporary therapeutics: an update on shark VAntibody therapeutics · 2020Review
- Advances in the Production and Batch Reformatting of Phage Antibody Libraries.Molecular biotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundMalaria rapid diagnostic tests (RDTs) represent an important antibody based immunoassay platform. Unfortunately, conventional monoclonal antibodies are subject to degradation shortening shelf lives of RDTs. The variable region of the receptor (V
methodsIn this study, new binders derived from shark V
resultsThe primary V
conclusionsTarget-specific bacteriophage V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.